5篇
您的检索式：作者名="QUESSADA A"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficient Cooling and Trapping of Strontium Atoms显示文摘 | Courtillot I Quessada A Kovacich R P | 2003 | Opt Lett2003，28，6： | 1 |
| 2 | Efficient cooling and trapping of strontium atoms显示文摘 | A Quessada R P Kovacich | 2003 | Optics Letters2003，28，6： | 1 |
| 3 | Efficient Cooling and Trapping of Strontium Atoms显示文摘 | COURTILLOT I QUESSADA A KOVACICH R P | 2003 | OptLett2003，28，： | 1 |
| 4 | Cold Strontium Atoms for an Optical Frequency Standard显示文摘 | COURTILLOT I QUESSADA A KOVACICH R P | 2003 | IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASURMENT2003，52，2： | 1 |
| 5 | Metabolic aspects behind ageing and neurodegeneration reveal new ways forward for therapy in motorneurone(ALS) and Parkinson diseases显示文摘Human beings evolved to run over a relatively short evolutionary time scale, ~1 million years, 2-3 million years ago, markedly increasing metabolic rate and VO2max, compared with other primates, while increasing brain size,and lifespan. Ageing leads to precise declines in performance and metabolism(VO2max): are there links with ageing-related diseases? Glucocerebrosidase(GCase;GBA1 subtype) mutations are the most common cause of Parkinson Disease,where there is lysosomal disruption and a reciprocal feedback between glucosylceramide and a-synuclein. We have shown that GBA2 is elevated and, using metabolomics, that ceramide and glucosylceramide levels are critically modified presymptomatically and at early stage in the spinal cord of superoxide dismutase1 mutant mice(SOD1G86R, ALS model),and lipid metabolism is massively changed at end stage disease. Modification of glucosylceramide synthase(GCS), and GCase activites shows that inhibiting GCS is deleterious and inhibiting GCase is beneficial to both neuromuscular junction function in sciatic nerve crush, and also grip strength and survival in the SOD1G86R model. Ambroxol(3 mmol·L-1 in drinking water), a glucocerebrosidase chaperone, accelerated recovery of NMJ function in sciatic nerve crush, and ameliorated grip strength and survival in the SOD1G86R model. Ambroxol is phase 2 ready in ALS and starting phase 3 in Parkinson disease. | A BOUSCARY C QUESSADA A HENRIQUES JP LOEFFLER M SPEDDING | 2019 | 中国药理学与毒理学杂志2019，33，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员